RAPP · Rapport Therapeutics, Inc.
$25.76
+1.70% last session
End-of-day data · close of 2026-10-27
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-5.0
Dividend yield
0.0%
Beta
1.22
Avg volume
1M
Employees
0K
Daily Change %
1.70%
5 Days Change
-4.52%
10 Days Change
-8.12%
30 Days Change
-25.30%
60 Days Change
-48.06%
Month to Day Change
-22.84%
Year to Day Change
-16.51%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RAPP
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
Wells Fargo
Overweight$50.00
+97.4% vs priceUBS
Buy$71.00
+180.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Jones Trading | Maintains | Buy | $50.00 → $82.00 |
| 2026-10-21 | Wells Fargo | Maintains | Overweight | $51.00 → $50.00 |
| 2026-10-21 | Guggenheim | Maintains | Buy | $65.00 → $70.00 |
| 2026-10-20 | HC Wainwright & Co. | Reiterates | Buy | $66.00 |
| 2026-10-20 | BTIG | Maintains | Buy | $75.00 → $89.00 |
| 2026-10-15 | UBS | Initiates | Buy | $0.00 → $71.00 |
| 2026-10-15 | Wolfe Research | Initiates | Outperform | $0.00 → $50.00 |
| 2026-10-06 | Guggenheim | Initiates | Buy | $0.00 → $65.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-27
- neutral: RSI (14): RSI is 31 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 32.5% below the 50-day MA ($38.15).
- bearish: Price vs 200-day MA: Trading 27.8% below the 200-day MA ($35.69).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.09) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($24.37).
RAPP Price Chart
Loading chart for RAPP…
Fundamentals
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.